Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ORMP's Cash to Debt is ranked higher than
80% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. ORMP: No Debt )
ORMP' s 10-Year Cash to Debt Range
Min: 1.06   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ORMP's Interest Coverage is ranked higher than
63% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ORMP: No Debt )
ORMP' s 10-Year Interest Coverage Range
Min: 128.16   Max: 9999.99
Current: No Debt

128.16
9999.99
F-Score: 3
Z-Score: 35.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -33.31
ORMP's ROE (%) is ranked higher than
74% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ORMP: -33.31 )
ORMP' s 10-Year ROE (%) Range
Min: -8090   Max: -39.39
Current: -33.31

-8090
-39.39
ROA (%) -32.15
ORMP's ROA (%) is ranked higher than
72% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. ORMP: -32.15 )
ORMP' s 10-Year ROA (%) Range
Min: -468.93   Max: -37.4
Current: -32.15

-468.93
-37.4
ROC (Joel Greenblatt) (%) -51875.00
ORMP's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. ORMP: -51875.00 )
ORMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -313200   Max: 242.89
Current: -51875

-313200
242.89
EBITDA Growth (3Y)(%) 31.70
ORMP's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ORMP: 31.70 )
ORMP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.8   Max: 57
Current: 31.7

-10.8
57
EPS Growth (3Y)(%) 28.80
ORMP's EPS Growth (3Y)(%) is ranked higher than
92% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ORMP: 28.80 )
ORMP' s 10-Year EPS Growth (3Y)(%) Range
Min: -24.7   Max: 183
Current: 28.8

-24.7
183
» ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
ORMP's P/B is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ORMP: 1.90 )
ORMP' s 10-Year P/B Range
Min: 0   Max: 28.2
Current: 1.9

0
28.2
Current Ratio 29.67
ORMP's Current Ratio is ranked higher than
97% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. ORMP: 29.67 )
ORMP' s 10-Year Current Ratio Range
Min: 0.13   Max: 67.68
Current: 29.67

0.13
67.68
Quick Ratio 29.67
ORMP's Quick Ratio is ranked higher than
97% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ORMP: 29.67 )
ORMP' s 10-Year Quick Ratio Range
Min: 0.13   Max: 67.68
Current: 29.67

0.13
67.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.90
ORMP's Price/Net Cash is ranked higher than
98% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. ORMP: 1.90 )
ORMP' s 10-Year Price/Net Cash Range
Min: 2.57   Max: 139.2
Current: 1.9

2.57
139.2
Price/Net Current Asset Value 1.90
ORMP's Price/Net Current Asset Value is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. ORMP: 1.90 )
ORMP' s 10-Year Price/Net Current Asset Value Range
Min: 2.57   Max: 139.2
Current: 1.9

2.57
139.2
Price/Tangible Book 1.90
ORMP's Price/Tangible Book is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. ORMP: 1.90 )
ORMP' s 10-Year Price/Tangible Book Range
Min: 2.56   Max: 75.6
Current: 1.9

2.56
75.6
Price/DCF (Projected) 10.40
ORMP's Price/DCF (Projected) is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ORMP: 10.40 )
ORMP' s 10-Year Price/DCF (Projected) Range
Min: 14.28   Max: 40.56
Current: 10.4

14.28
40.56
Earnings Yield (Greenblatt) -23.10
ORMP's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ORMP: -23.10 )
ORMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -666.7   Max: 9.3
Current: -23.1

-666.7
9.3

Analyst Estimate

Aug15

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:OJU1.Germany,
Oramed Pharmaceuticals Inc. was incorporated on April 12, 2002, under the laws of the State of Nevada. It is a pharmaceutical Company engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. The Company is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in Phase 2 clinical trials. The Company plans to continue to conduct clinical trials to show the effectiveness of its technology. It filed two additional provisional patents for a suppository application to its technology portfolio. The first patent focuses on a rectal application for insulin. The second patent focuses on the usage of this rectal application to other polypeptides that at present are only available in injection. On September 16, 2008 it announced the launch of pre-clinical trials of ORMD 0901, a GLP1-analog. The Company has agreements with Vetgenerics Research G. Ziv Ltd., a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.
» More Articles for ORMP

Headlines

Articles On GuruFocus.com
Coverage Initiation Report Focuses on Oramed Pharmaceuticals Nov 11 2014 

More From Other Websites
Oramed to Present at the ROTH Conference Mar 04 2015
Oramed to Present Poster at the GTC Protease Inhibitors in Drug Discovery Conference Feb 19 2015
Oramed to Present Poster at the GTC Protease Inhibitors in Drug Discovery Conference Feb 19 2015
Oramed to Present at the BIO CEO & Investor Conference Feb 05 2015
Oramed to Present at the BIO CEO & Investor Conference Feb 05 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 28 2015
Oramed Pharmaceuticals Inc. Issues Letter to Shareholders Jan 28 2015
Oramed Granted Patent in Israel for Oral Administration of GLP-1 Jan 16 2015
Oramed Granted Patent in Israel for Oral Administration of GLP-1 Jan 16 2015
ORAMED PHARMACEUTICALS INC. Financials Jan 14 2015
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jan 08 2015
Oramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company Dec 03 2014
Oramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company Dec 03 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Dec 02 2014
Oramed Pharmaceuticals at LD MICRO "Main Event" Micro-Cap Growth Conference on December 2, 2014 Dec 01 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Nov 14 2014
Coverage Initiation Report Focuses on Oramed Pharmaceuticals Nov 11 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 04 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 03 2014
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes Oct 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK